Get started
Author

Matthew S. Nord

Observed names: Matthew Nord, Matthew S Nord
ORCID: 0000-0002-0752-8030
Observed ORCID: 0000-0002-0752-8030
OpenAlex ID: A5014785883
Nuclear transport factors: global regulation of mitosis
2015 · Douglass J Forbes, Anna Travesa, et al. · Current Opinion in Cell Biology · 129
Transportin acts to regulate mitotic assembly events by target binding rather than Ran sequestration
2014 · Cyril Bernis, Beth Swift-Taylor, et al. · Molecular Biology of the Cell · 30
PDF
Reprint of “Nuclear transport factors: global regulation of mitosis”
2015 · Douglass J Forbes, Anna Travesa, et al. · Current Opinion in Cell Biology · 14
Exportins can inhibit major mitotic assembly events in vitro: membrane fusion, nuclear pore formation, and spindle assembly
2020 · Matthew S. Nord, Cyril Bernis, et al. · Nucleus · 11
449 Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the dual MEK inhibitor, IMM-6-415, enhances PD1 and CTLA4 checkpoint blockade in RAS mutant tumors
2022 · Brett Hall, Anna Travesa, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Supplementary Table S4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Data from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 6 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 4 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Table S2 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 5 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Table 1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Figure 3 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Supplementary Figure S1 from Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al.
Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS - and RAF -Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF Bypass
2026 · Sarah Kolitz, Anna Travesa, et al. · Cancer Research
Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus sotorasib or adagrasib in KRAS mutant pancreatic tumors.
2022 · Peter J. King, Matthew Nord, et al. · Journal of Clinical Oncology
Analysis of Regulation of Major Mitotic Assembly Events In Vitro by Nuclear Import and Export Receptors
2018 · Matthew Nord · eScholarship (California Digital Library)
Works count: 21
Citation count: 186
H-index: 4
I10-index: 4
Year
Topic
Type